GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,045 | 5,672 | 2,465 | 5,358 | 7,286 |
| Marketable Securities | 17,854 | 10,836 | 18,319 | 18,367 | 19,454 |
| TOTAL | $19,937 | $16,562 | $20,872 | $23,947 | $27,193 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 149 | 174 | 199 | 223 | 246 |
| TOTAL | $149 | $174 | $199 | $223 | $246 |
| Total Assets | $20,086 | $16,736 | $21,071 | $24,170 | $27,439 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,131 | 3,140 | 3,325 | 7,263 | 8,113 |
| Accrued Expenses | 829 | 1,669 | 1,537 | 1,129 | 1,170 |
| Other current liabilities | N/A | 19 | 57 | 115 | 120 |
| TOTAL | $4,076 | $4,938 | $5,025 | $8,610 | $9,503 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,957 | 64 | 92 | 120 | 147 |
| TOTAL | $2,957 | $64 | $92 | $120 | $147 |
| Total Liabilities | $7,033 | $5,002 | $5,117 | $8,730 | $9,650 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,247 | 1,226 | 1,084 | 1,035 | 1,016 |
| Common Shares | 37 | 33 | 33 | 31 | 32 |
| Retained earnings | -674,695 | -674,468 | -668,884 | -662,003 | -659,024 |
| Other shareholders' equity | 1 | 1 | 1 | 1 | 1 |
| TOTAL | $13,053 | $11,734 | $15,954 | $15,440 | $17,789 |
| Total Liabilities And Equity | $20,086 | $16,736 | $21,071 | $24,170 | $27,439 |